# GLP-1 drugs and muscle preservation

Rating: Early — Mostly animal or cell studies; few or uncontrolled human data
Type: Guide
Updated: 2026-10-14
Canonical: https://heretic.bio/articles/glp-1-muscle-preservation.html

> About 25-45% of weight lost on GLP-1 drugs is lean tissue, though 2026 analyses contest whether that is disproportionate to ordinary dieting. The strongest mitigation data is BELIEVE, a 507-person phase 2 trial where bimagrumab plus semaglutide cut fat mass 45.7% while losing only 2.9% lean mass at week 72. A five-arm trial in hypogonadal men found testosterone plus resistance training produced net lean-mass gain. Larger trials with MRI muscle endpoints read out in 2027.

## Problem Statement

25–45% of weight lost on GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) is lean tissue, not fat mass, per DXA substudies. This creates secondary market need for muscle preservation protocols in longevity and weight-management clinics.

## Human Clinical Trial Evidence (Primary Sources)

### Key Trials Showing Lean Mass Loss

  * **SURPASS-3 MRI post-hoc (Tirzepatide)** : MRI substudy (n=246): muscle volume decrease proportional to weight loss; maintained fat-free muscle volume, improved muscle quality (less fat infiltration). web:0



Meta-analyses (2025–2026) confirm heterogeneity: lean mass loss 15–60% of total weight lost depending on measurement (DXA vs MRI) and population. See 2026 counter-evidence section below — the "muscle wasting" framing is increasingly contested.

Animal/in-vitro: Limited; mouse models show predominant fat loss with minor LBM decrease (Langer et al. 2026, Cell Rep Med).

## 2026 Practice-Changing Evidence

### 1\. Bimagrumab + Semaglutide — Full Publication (BELIEVE) — PMID [41772149](https://pubmed.ncbi.nlm.nih.gov/41772149/)

**Heymsfield SB et al. "Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial."_Nature Medicine_. 32(3):... (Mar 2026). PMID [41772149](https://pubmed.ncbi.nlm.nih.gov/41772149). DOI [10.1038/s41591-026-04204-0](https://doi.org/10.1038/s41591-026-04204-0). [PMC13004672](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13004672/). Trial [NCT05616013](https://clinicaltrials.gov/study/NCT05616013).**

Double-blind, placebo-controlled, full factorial (2×2 + monotherapy arms, 9 groups total), 26 sites (US/Australia/New Zealand), n=507 randomized, BMI ≥30 or ≥27 + obesity complication (no diabetes). IV bimagrumab 10 or 30 mg/kg every 12 weeks; SC semaglutide 1.0 or 2.4 mg weekly. 48-week primary period → 72-week OLE → 104-week withdrawal follow-up (still ongoing). Funded by Versanis Bio (acquired by Eli Lilly 2023).

**Week 48 (treatment-regimen estimand, LSM ± SE):**

Arm | Body weight (kg) | Fat mass (kg) | Lean mass (kg) | Fat-loss index  
---|---|---|---|---  
Placebo | −3.3 ± 1.4 | −1.9 ± 1.2 | −0.5 ± 0.7 | —  
Bimag 10 mg/kg | −6.0 ± 1.4 | −5.7 ± 1.2 | +0.5 ± 0.7 | —  
**Bimag 30 mg/kg** | **−9.3 ± 1.3** | **−8.6 ± 1.2** | **+0.4 ± 0.7** | **100%** (all weight lost = fat)  
Sema 1.0 mg | −9.8 ± 1.3 | −6.7 ± 1.0 | −2.6 ± 0.6 | —  
**Sema 2.4 mg** | **−14.2 ± 1.2** | **−9.6 ± 1.0** | **−3.9 ± 0.6** | **71.1%**  
Bimag 10 + Sema 2.4 | −13.9 ± 1.3 | −12.2 ± 1.1 | −0.6 ± 0.6 | —  
  
**Week 72 (efficacy estimand, LSM):** \- Bimag 30: −10.8% body weight, **−28.5% fat mass** , **+2.5% lean mass** (P<0.001 vs placebo) \- Sema 2.4: −15.7% body weight, **−27.8% fat mass** , **−7.4% lean mass** \- **High-dose combo: −22.1% body weight, −45.7% fat mass, only −2.9% lean mass** (P<0.001 combo vs sema 2.4 for lean preservation)

**Other notable endpoints:** \- 94.0% of high-dose-combo participants achieved ≥30% fat-mass reduction at week 72 (vs 36.4% sema 2.4, 50.0% bimag 30) \- Mean percent body fat: 43.7% → 32.5% with high-dose combo; 41.9% → 37.9% with sema 2.4 \- Estimated VAT: −58.2% (combo) vs −35.8% (sema) at week 72 \- hsCRP **down up to 83%** , adiponectin substantially increased \- Prediabetic subgroup: **100% reversion to normoglycemia** in some two-drug combination groups \- Appendicular lean mass (skeletal-muscle proxy): better preserved with combo vs sema alone (Table 2 / Extended Data Table 1) \- Total body BMD small increases across active arms (consistent with reduced mechanical loading + anabolic effect of preserved lean)

**Safety (bimagrumab signature AEs):** muscle spasms, diarrhea, acne (ActRII blockade → known class effect). Semaglutide AEs as expected (nausea, diarrhea, constipation, fatigue). Discontinuation for AE: bimagrumab 14–21% vs sema 3.6–8.8% vs combo 5.3–12.5% vs placebo 3.6%. No deaths. Importantly: combo did NOT stack bimagrumab's discontinuation rate — the combination was better tolerated than bimagrumab monotherapy.

**Critical interpretation:** \- High-dose combo achieved **fat-mass reduction (45.7%) in the range reported for bariatric surgery** at similar timepoints \- Combination produced "nearly additive" fat loss because mechanisms are independent: sema targets CNS appetite, bimag targets ActRII→ALK7 adipose lipid mobilization + ALK4 muscle anabolism \- PMID [41772149](https://pubmed.ncbi.nlm.nih.gov/41772149/) confirms the 2024 ADA late-breaking preview numbers but provides week-72 OLE data showing continued divergence of fat vs lean curves through the open-label extension \- **Limitation:** DXA measures lean mass, not muscle directly (includes connective tissue, water); intramuscular fat quantified only in earlier bimagrumab-T2D study. Phase 3 with MRI muscle-volume primary endpoint is the next data milestone.

### 2\. CagriSema Body Composition — REDEFINE-1 DXA Substudy (ECO 2026, May 2026)

Presented by Ravussin (Pennington) at European Congress on Obesity 2026; DXA subgroup, week 68: \- CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg): **−23.9%** body weight — vs semaglutide 2.4 mg −16.6%, cagrilintide −15.0%, placebo −2.8%. \- Composition of loss: **66.9% fat mass / 33.1% lean soft tissue** (CagriSema); semaglutide 69.7% fat; cagrilintide 62.9% fat. \- In CagriSema responders losing ≥30% body weight, lean-soft-tissue share of loss _increased_ over time (51.3% → 63.2% between measurement points) — i.e., loss became progressively more fat-predominant; **muscle strength was preserved**. \- Read-through: amylin co-agonism does not worsen lean-mass fraction vs GLP-1 alone at class level.

### 3\. REDEFINE-4 Head-to-Head + Regulatory Milestone (Feb 2026)

  * **CagriSema NDA submitted to FDA December 2025** (weight management, based on REDEFINE-1/2); decision expected **late 2026**. First amylin-combination approval would expand the muscle-preservation adjunct market (cagrilintide's lean fraction profile is slightly worse than semaglutide's in REDEFINE-1 DXA).



### 4\. 2026 Counter-Evidence — "Disproportionate Muscle Loss" Challenged

The debate has tightened; balance both directions: \- **Langer HT et al. Cell Rep Med. 2026;7:102665** — "Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans": lean loss proportional to what diet-induced weight loss of same magnitude produces. \- **SEMALEAN (Alissou M et al. Diabetes Obes Metab. 2026;28:112–121)** — semaglutide fat/lean mass + muscle _function_ outcomes. \- **Sawicka-Gutaj N et al. Int J Obes. 2026** (systematic review + network meta-analysis; doi [10.1038/s41366-026-02088-1](https://doi.org/10.1038/s41366-026-02088-1)) — class-level body-composition comparison. \- **Corso H et al. Front Endocrinol. 2026;17:1834580** (July 2026) — real-world tirzepatide body composition. \- **medRxiv 2026.04.11.26350687** — phenotyping study: baseline phenotype determines position on fat-loss ↔ mixed-loss spectrum; most reproducible signal = greater relative LBM decline with **tirzepatide vs semaglutide**.

Synthesis: lean loss is real but proportional-ish; the clinical concern concentrates in sarcopenic-risk, elderly, low-baseline-lean cohorts — exactly where DXA/MRI monitoring and resistance training matter most.

## Mitigation Strategies and Combination Evidence

**Ongoing RCT — LEAN-PREP (primary protocol source)** : Alawadhi AA et al. BMJ Open. 2026;16(4):e116911. doi [10.1136/bmjopen-2025-116911](https://doi.org/10.1136/bmjopen-2025-116911). Trial reg: [NCT06885736](https://clinicaltrials.gov/study/NCT06885736) (recruiting).

**Design** : Single-centre (Dasman Diabetes Institute), 6-month, 1:1:1:1 RCT, n=232 obese adults (BMI 27–45) starting semaglutide or tirzepatide. \- Arms: Control (usual care) vs Resistance exercise (home-based 3×/wk, progressive) vs Protein (1.6 g/kg/day) vs Combined. \- Primary outcome: MRI quadriceps CSA (vastus lateralis). Secondary: DEXA body comp, strength/function, liver fat/stiffness (MRI PDFF/MRE), QoL, sleep, biomarkers. \- Protein target based on Morton meta-regression (1.6 g/kg threshold).

**Pharmacologic adjunct hierarchy (Aug 2026):** 1\. **Bimagrumab + semaglutide** — only combination with full published Ph2 RCT evidence (Heymsfield, Nat Med 2026). Not approved; IV administration. 2\. **Myostatin/activin-pathway inhibitors** (Regeneron, BioAge, Veru) — Ph1/2; mechanism validated by bimagrumab data. 3\. **Resistance exercise + protein 1.6 g/kg/day** (the protein level used in trials), the most accessible option while LEAN-PREP results are pending; zero cost, functional-outcome track record. 4\. Monitoring: baseline + serial DXA or MRI in at-risk cohorts (older, low lean mass, rapid losers >1.5%/wk).

### 5\. Multimodal Anabolic Stack — TRT + Resistance Training + High-Protein (2026 RCT)

**Reference:** Abstract 470, _J Sex Med_ 2026; doi [10.1093/jsxmed/qdag118.413](https://doi.org/10.1093/jsxmed/qdag118.413) — "Preservation of Lean Mass under GLP-1/GIP-Based Pharmacotherapy: Effects of Testosterone and Resistance Training — A Five-Arm, Randomized, Open-Label Parallel-Group Study in Obese Men."

  * 26-week, multicenter, randomized, open-label (assessors blinded), n=266 obese men, BMI ≥30, age 18–70, total testosterone <3.5 ng/mL with hypogonadism-compatible symptoms, eligible for GLP-1/GIP therapy.
  * Primary endpoint: change in fat-free mass by bioimpedance. Secondary: body weight, waist circumference, maximal strength (leg press/row/bench), IIEF.



**FFM share of weight loss (26 weeks, by arm):**

Arm | FFM share of weight loss | Strength change (leg press) | IIEF (sexual function)  
---|---|---|---  
GLP-1/GIP alone | **38%** | up to **−23%** | **−2.1** (decline)  
\+ TRT | 26% | (modest gain) | +3.8 to +4.6  
\+ TRT + training | 16% | (improving) | +3.8 to +4.6  
— | **0% — net FFM gain +4.2%** | **+43.4% leg press, +31.4% row, +27.1% bench** | **+4.6**  
\+ high-protein alone | 32% | partial | —  
  
**Tradeoff observation:** Greatest absolute weight loss in GLP-1/GIP-only arm (−12.1 kg) but also highest muscle loss. Waist circumference reduction was LEAST in the GLP-1/GIP-only arm (−6.3 cm) and MOST in the combined arm (−8.9 cm) — i.e., the anabolic stack changes body recomposition more than absolute weight loss.

**Critical interpretation:** First RCT to demonstrate that pharmacologic + behavioral + hormonal synergy can produce **net FFM gain during GLP-1 therapy** in hypogonadal men. Major caveat: open-label design, single-gender (men only), industry-symposium framing (J Sex Med abstract session), and protein target (2.2 g/kg FFM/day) is ~38% above LEAN-PREP's 1.6 g/kg/day. Generalization to eugonadal men and to women not established.

### 6\. RESIST — Phase IV Resistance Training + Tirzepatide ([NCT07777575](https://clinicaltrials.gov/study/NCT07777575), started 2026-08-17)

  * **Sponsor:** Technical University of Munich, with EGYM SE (smart-gym equipment partner).
  * **Design:** Phase IV, randomized, double-blind (assessor), parallel-group, n=150 adults with obesity.
  * **Primary outcome:** Change in **contractile thigh muscle volume by MRI** (mL) — first large RCT using direct MRI muscle volume as the primary endpoint (more rigorous than DXA lean mass).
  * **Secondary:** muscle mass by bioimpedance, training adherence (automatic EGYM device logs), strength, body composition.
  * **Completion:** 2027-05-31 (primary).
  * **Significance:** Will provide the highest-quality causal evidence for the "resistance training alone preserves muscle on GLP-1/GIP" claim that LEAN-PREP (lifestyle + protein) is testing. Watch for late-2027/2028 readouts.



## Regulatory & Claims Audit

  * No FDA approval for muscle-preservation claims with GLP-1s; bimagrumab not approved for obesity. Clinics selling "GLP-1 muscle protection" stacks are ahead of evidence — only exercise/protein has guideline backing.
  * CagriSema NDA (Dec 2025, decision late 2026) is the class regulatory event to watch; orforglipron/oral GLP-1s will re-run the same lean-mass debate.

## Sources

1. Heymsfield SB et al. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine . PMID 41772149 . DOI 10.1038/s41591-026-04204-0 . PMC13004672 . NCT05616013 . The single most important paper in this file. (PubMed 41772149, DOI 10.1038/s41591-026-04204-0, PMC13004672, NCT05616013)
2. DOI 10.1038/s41366-026-02088-1 (DOI 10.1038/s41366-026-02088-1)
3. DOI 10.1136/bmjopen-2025-116911 (DOI 10.1136/bmjopen-2025-116911)
4. Alawadhi AA et al. (2026). LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): protocol for a randomised controlled trial. BMJ Open 16(4):e116911. PMID 42020128 . NCT06885736 . (NCT06885736, PubMed 42020128)
5. Abstract 470 (2026). Preservation of Lean Mass under GLP-1/GIP-Based Pharmacotherapy: Effects of Testosterone and Resistance Training — A Five-Arm, Randomized, Open-Label Parallel-Group Study in Obese Men. J Sex Med . doi 10.1093/jsxmed/qdag118.413 . (DOI 10.1093/jsxmed/qdag118.413)
6. NCT07777575 (RESIST, started 2026-08-17). Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide — Phase IV, Technical University of Munich + EGYM SE. Primary completion 2027-05-31. (NCT07777575)